ADVFN ADVFN

Hot Features

Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Biomarin Phar Dl 001

Biomarin Phar Dl 001 (1BMRN)

0,00
0,00
(0,00%)
Fermé 24 Juin 5:30PM

Biomarin Phar Dl 001 (1BMRN) Action

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Statistiques et détails clés

Dernier
-
( - )
Prix Achat
-
Prix Vente
-
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,00 Plage de 52 semaines 0,00
Cap du marché
Clôture Veille
-
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume financier
-
VWAP
-
Volume moyen (3 m)
1 996 385 €
Actions en circulation
193 284 438
Rendement du Dividende (LTM)
Ratio Cours sur Bénéfices
39,16
Bénéfice par action (BPA)
1,4
Chiffre d'affairess (LTM)
3,24B
Bénéfice net (LTM)
268,74M

À propos de Biomarin Phar Dl 001

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products i... BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company’s products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California. Show more

Secteur
Healthcare
Industrie
Biotechnology & Life Sciences
Site Web
Siège social
San Rafael, United States
Fondé
1996
Biomarin Phar Dl 001 est coté dans le secteur Healthcare de la Italian Stock Exchange avec le ticker 1BMRN. Le dernier cours de clôture d'Biomarin Phar Dl 001 était de -. Au cours de la dernière année, les actions de Biomarin Phar Dl 001 ont été négociées dans une fourchette de prix de 0,00 € à 0,00 €.

Biomarin Phar Dl 001 compte actuellement 193 284 438 actions en circulation. Biomarin Phar Dl 001 a un ratio cours/bénéfice (ratio PE) de 39.16.

1BMRN Dernières nouvelles

Aucune actualité à afficher pour le moment.
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000DE
40000000DE
120000000DE
260000000DE
520000000DE
1560000000DE
2600000000DE

1BMRN - Frequently Asked Questions (FAQ)

What is the current Biomarin Phar Dl 001 share price?
The current share price of Biomarin Phar Dl 001 is 0,00 €
How many Biomarin Phar Dl 001 shares are in issue?
Biomarin Phar Dl 001 has 193 284 438 shares in issue
What is the 1 year trading range for Biomarin Phar Dl 001 share price?
Biomarin Phar Dl 001 has traded in the range of 0,00 € to 0,00 € during the past year
What is the PE ratio of Biomarin Phar Dl 001?
The price to earnings ratio of Biomarin Phar Dl 001 is 39,16
What is the cash to sales ratio of Biomarin Phar Dl 001?
The cash to sales ratio of Biomarin Phar Dl 001 is 3,26
What is the registered address of Biomarin Phar Dl 001?
The registered address for Biomarin Phar Dl 001 is 770 Lindaro Street, San Rafael, California, 94901
What is the Biomarin Phar Dl 001 website address?
The website address for Biomarin Phar Dl 001 is www.biomarin.com
Which industry sector does Biomarin Phar Dl 001 operate in?
Biomarin Phar Dl 001 operates in the Biotechnology & Life Sciences sector

1BMRN Transactions

Plus

Transactions différées

Pour obtenir des transactions en temps réel, améliorez votre compte

Passer à la version en temps réel
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock